Recent Stock Performance
Company s 52-week low was at $20.47
Price action over last quarter: Up 32.97%
Company Description
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Related Articles (NEO)
NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc.: NeoGenomics Reports 18% Revenue Growth to $126 Million in the Fourth Quarter
Consolidated revenue increased 18% to $126 million
Clinical Services revenue increased 14% to $107 million
Pharma Services revenue increased 43% to $19 million
Pharma Services backlog increased 60% to $209 million
FT. MYERS, FL / ACCESSWIRE / February 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced fourth-quarter and full-year 2020 results for the period ended December 31, 2020.
Douglas M. VanOort, the company s Chairman and CEO said 2020 was a remarkable year for NeoGenomics, and one that obviously no one could have prepared for or anticipated. We are proud of the outstanding NeoGenomics team for responding and excelling in this most challenging environment. They never wavered from delivering high-quality results for the physicians and patients we serve.
02 19 21 -- Providers Ready To Help With Your Pharmaceutical Packaging Projects pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.